AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8848903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 51
Study 1966593 — intervention group
Group type: EXPERIMENTAL
Intervention: glypressin
Number of subjects: 54
Study 1966593 — intervention group
Group type: COMPARATOR
Intervention: vasopressin
Number of subjects: 54
Study 378798 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfason (hydrocortisone‐17 abutyrate)
Number of subjects: 200
Study 378798 — intervention group
Group type: COMPARATOR
Intervention: Fluorinated corticoid
Number of subjects: 200
Study 30328216 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional AD-protocol
Number of subjects: 54
Study 30328216 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-supported AD-protocol
Number of subjects: 54
Study 30328216 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL) control group
Number of subjects: 54
Study 28161365 — intervention group
Group type: COMPARATOR
Intervention: Water without licking
Number of subjects: 24
Study 28161365 — intervention group
Group type: EXPERIMENTAL
Intervention: Water with licking
Number of subjects: 24
Study 28161365 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice alone
Number of subjects: 24
Study 28161365 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice with licking
Number of subjects: 24
Study 26509605 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week peginterferon/ribavirin treatment
Number of subjects: 152
Study 26509605 — intervention group
Group type: COMPARATOR
Intervention: 48-week peginterferon/ribavirin treatment
Number of subjects: 152
Study 24122698 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous electrical neurostimulation (PENS) of dermatome T6 with a 1,200-Kcal diet (group 1)
Number of subjects: 105
Study 24122698 — intervention group
Group type: COMPARATOR
Intervention: 1,200-Kcal diet alone (group 2)
Number of subjects: 105
Study 24122698 — intervention group
Group type: COMPARATOR
Intervention: PENS of posterior tibial nerve (group 3)
Number of subjects: 105
Study 21083855 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg per day) for 4 weeks
Number of subjects: 19
Study 21083855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 19299805 — intervention group
Group type: EXPERIMENTAL
Intervention: NS1209 (322 mg)
Number of subjects: 13
Study 19299805 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg/kg)
Number of subjects: 13
Study 19299805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 17410418 — intervention group
Group type: EXPERIMENTAL
Intervention: History of two or more episodes of major depression
Number of subjects: 138
Study 17410418 — intervention group
Group type: COMPARATOR
Intervention: History of one episode of major depression
Number of subjects: 138
Study 17410418 — intervention group
Group type: COMPARATOR
Intervention: No history of major depression
Number of subjects: 138
Study 15329598 — intervention group
Group type: EXPERIMENTAL
Intervention: OTF (10 microg/kg) after hepatic/intestinal CYP3A induction by rifampin
Number of subjects: 12
Study 15329598 — intervention group
Group type: EXPERIMENTAL
Intervention: OTF (10 microg/kg) after hepatic/intestinal CYP3A inhibition by troleandomycin
Number of subjects: 12
Study 15329598 — intervention group
Group type: EXPERIMENTAL
Intervention: OTF (10 microg/kg) after selective intestinal CYP3A inhibition by grapefruit juice
Number of subjects: 12
Study 15329598 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 12
Study 11137181 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 mcg/daily)
Number of subjects: 12
Study 11137181 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 9846791 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol hydrochloride (Decapinol Mouthwash)
Number of subjects: 68
Study 9846791 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate (Hibitane Dental)
Number of subjects: 68
Study 9846791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 9747742 — intervention group
Group type: EXPERIMENTAL
Intervention: Single breath test for CO2 (SBT‐CO2)
Number of subjects: 223
Study 9747742 — intervention group
Group type: COMPARATOR
Intervention: Lung scintigraphy
Number of subjects: 223
Study 2067508 — intervention group
Group type: EXPERIMENTAL
Intervention: Mallinckrodt Hi‐Lo‐Evac tube with pharyngeal pack
Number of subjects: 60
Study 2067508 — intervention group
Group type: EXPERIMENTAL
Intervention: Mallinckrodt Hi‐Lo‐Evac tube without pharyngeal pack
Number of subjects: 60
Study 2067508 — intervention group
Group type: COMPARATOR
Intervention: Portex blue line tube with pharyngeal pack
Number of subjects: 60
Study 6342836 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate, 10 mg twice daily
Number of subjects: 1884
Study 31754161 — intervention group
Group type: EXPERIMENTAL
Intervention: DM with high P2O5 (P1)
Number of subjects: 5
Study 31754161 — intervention group
Group type: COMPARATOR
Intervention: Control (P0)
Number of subjects: 5
Study 31754161 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic P (P3)
Number of subjects: 5
Study 29166359 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse specimen extraction
Number of subjects: 165
Study 29166359 — intervention group
Group type: COMPARATOR
Intervention: Midline specimen extraction
Number of subjects: 165
Study 29166359 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-protocol analysis for transverse
Number of subjects: 165
Study 29166359 — intervention group
Group type: COMPARATOR
Intervention: Per-protocol analysis for midline
Number of subjects: 165
Study 27710972 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib beyond progression (n = 21; median duration of continued gefitinib use: 4.2 months)
Number of subjects: 70
Study 27710972 — intervention group
Group type: COMPARATOR
Intervention: Stopped gefitinib treatment upon disease progression (n = 35)
Number of subjects: 70
Study 23981503 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact game
Number of subjects: 23
Study 23981503 — intervention group
Group type: COMPARATOR
Intervention: Non-contact game
Number of subjects: 23
Study 22370530 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC‐HFA 74 micrograms
Number of subjects: 1111
Study 22370530 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC‐HFA 148 micrograms
Number of subjects: 1111
Study 22370530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1111
Study 21280422 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous-containing sodium fluoride dentifrice
Number of subjects: 60
Study 21280422 — intervention group
Group type: COMPARATOR
Intervention: Potassium nitrate positive control dentifrice
Number of subjects: 60
Study 18424480 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta therapy
Number of subjects: 20
Study 18424480 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 20
Study 15881949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumo 23 vaccine
Number of subjects: 45
Study 12519430 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/kg of filgrastim
Number of subjects: 131
Study 12519430 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg of filgrastim
Number of subjects: 131
Study 12519430 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/kg of filgrastim after transplantation
Number of subjects: 131
Study 12519430 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard chemotherapy without specified filgrastim dose)
Number of subjects: 131
Study 10889916 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridol mouthrinse (amine fluoride)
Number of subjects: 10
Study 10889916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 10
Study 9058693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ouabain (1 mg)
Number of subjects: 47
Study 9058693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 7939931 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron tablet 1 (60 mg elemental iron)
Number of subjects: 18
Study 7939931 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron tablet 2 (60 mg elemental iron)
Number of subjects: 18
Study 7939931 — intervention group
Group type: COMPARATOR
Intervention: Aqueous Fe(II)-sulphate solution (120 mg elemental iron)
Number of subjects: 18
Study 3510524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (90 mg/day in 3 divided doses)
Number of subjects: 25
Study 3510524 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/day in 3 divided doses)
Number of subjects: 25
Study 3510524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 25
Study 3510524 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 25
Study 29529975 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified stretching exercise program
Number of subjects: 127
Study 29529975 — intervention group
Group type: COMPARATOR
Intervention: Usual activities
Number of subjects: 127
Study 29116494 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT (CMD + PDT)
Number of subjects: 32
Study 26940585 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Home Offerings via the Mealtime Environment (HOME) Plus intervention
Number of subjects: 81
Study 24965551 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain packs of cigarettes
Number of subjects: 128
Study 24965551 — intervention group
Group type: COMPARATOR
Intervention: Branded packs of cigarettes
Number of subjects: 128
Study 22301361 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lateral retinacular lengthening
Number of subjects: 28
Study 22301361 — intervention group
Group type: COMPARATOR
Intervention: Open lateral retinacular release
Number of subjects: 28
Study 20813485 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4
Number of subjects: 20
Study 20813485 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 20
Study 17544636 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient psychotherapy (specific type not mentioned)
Number of subjects: 88
Study 17544636 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare-related costs
Number of subjects: 88
Study 17544636 — intervention group
Group type: EXPERIMENTAL
Intervention: Total societal costs
Number of subjects: 88
Study 16170175 — intervention group
Group type: EXPERIMENTAL
Intervention: L-BLP25 plus best supportive care (BSC)
Number of subjects: 171
Study 16170175 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 171
Study 12431827 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1200 mg/m² on days 1 and 8 plus carboplatin at an area under the curve of 5 mg/ml/min on day 1
Number of subjects: 0
Study 12431827 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1200 mg/m² on days 1 and 8 plus cisplatin 80 mg/m² on day 1 every 21 days
Number of subjects: 0
Study 7949831 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal FSH measurements in ovulatory patients
Number of subjects: 131
Study 7949831 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal FSH measurements in anovulatory patients
Number of subjects: 131
Study 3675403 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure suction drain
Number of subjects: 0
Study 3675403 — intervention group
Group type: COMPARATOR
Intervention: High pressure suction drain
Number of subjects: 0
Study 3675403 — intervention group
Group type: COMPARATOR
Intervention: Passive drain
Number of subjects: 0
Study 29650207 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based spiritual life review program
Number of subjects: 52
Study 29650207 — intervention group
Group type: COMPARATOR
Intervention: Control group (received the same program after the study)
Number of subjects: 52
Study 28872480 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (10 µg)
Number of subjects: 180
Study 28872480 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (137 µg)
Number of subjects: 180
Study 28872480 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (8 µg)
Number of subjects: 180
Study 28872480 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine and Phenylephrine
Number of subjects: 180
Study 26165735 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction pseudopolyp technique
Number of subjects: 112
Study 26165735 — intervention group
Group type: COMPARATOR
Intervention: Cold snare polypectomy
Number of subjects: 112
Study 26165735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 112
Study 23266540 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg) administered at bedtime
Number of subjects: 21
Study 23266540 — intervention group
Group type: COMPARATOR
Intervention: Captopril (not specified dosage)
Number of subjects: 21
Study 23266540 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention specified)
Number of subjects: 21
Study 21512499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 64
Study 19361598 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (≤325 mg/day)
Number of subjects: 13
Study 19361598 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 13
Study 19361598 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus extended-release dipyridamole (ER-DP)
Number of subjects: 13
Study 19361598 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel
Number of subjects: 13
Study 19361598 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation (warfarin and other vitamin K antagonists)
Number of subjects: 13
Study 17018383 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox 10 mg/kg/day (modified after 12 weeks)
Number of subjects: 40
Study 17018383 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox 10 mg/kg/day (mean dose 11.3 mg/kg/day)
Number of subjects: 40
Study 17018383 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (once-daily dosing)
Number of subjects: 40
Study 15466880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg at baseline, 30 mg at months 1, 2, 3, and 6)
Number of subjects: 57
Study 15466880 — intervention group
Group type: COMPARATOR
Intervention: Control (no pamidronate)
Number of subjects: 57
Study 15466880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 57
Study 15466880 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study 10906163 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-627 (20 mg)
Number of subjects: 9
Study 10906163 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-627 (5 mg)
Number of subjects: 9
Study 10906163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10906163 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 9
Study 9409566 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 273
Study 9409566 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 273
Study 8103655 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (200 micrograms)
Number of subjects: 11
Study 8103655 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (400 micrograms)
Number of subjects: 11
Study 8103655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3252453 — intervention group
Group type: EXPERIMENTAL
Intervention: CW dye laser treatment
Number of subjects: 20
Study 3252453 — intervention group
Group type: COMPARATOR
Intervention: CW argon laser treatment
Number of subjects: 20
Study 29486720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (200 μg)
Number of subjects: 42
Study 29486720 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal placebo
Number of subjects: 42
Study 27914744 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 468
Study 27914744 — intervention group
Group type: COMPARATOR
Intervention: Vaccine-naïve controls
Number of subjects: 468
Study 26183611 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5816 150 mg for 3 days
Number of subjects: 70
Study 26183611 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5816 5-150 mg for 3 days
Number of subjects: 70
Study 26183611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 26183611 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5816 (all doses)
Number of subjects: 70
Study 26183611 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without pretreatment NS5A resistance-associated polymorphisms
Number of subjects: 70
Study 26183611 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pretreatment NS5A resistance-associated polymorphisms
Number of subjects: 70
Study 24645552 — intervention group
Group type: EXPERIMENTAL
Intervention: S-amlodipine
Number of subjects: 127
Study 24645552 — intervention group
Group type: COMPARATOR
Intervention: Racemic amlodipine
Number of subjects: 127
Study 22093927 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAE plus cryoablation (Group B)
Number of subjects: 104
Study 22093927 — intervention group
Group type: COMPARATOR
Intervention: TRAE (Group A)
Number of subjects: 104
Study 19716484 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentaport ZX
Number of subjects: 60
Study 19716484 — intervention group
Group type: EXPERIMENTAL
Intervention: Raypex 5
Number of subjects: 60
Study 19716484 — intervention group
Group type: EXPERIMENTAL
Intervention: Elements Diagnostic Unit and Apex Locator
Number of subjects: 60
Study 17476010 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher glycated hemoglobin values
Number of subjects: 1144
Study 17476010 — intervention group
Group type: COMPARATOR
Intervention: Severe hypoglycemia
Number of subjects: 1144
Study 15507943 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of meperidine
Number of subjects: 407
Study 15507943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study 11675899 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg orally once daily for 12 weeks
Number of subjects: 123
Study 11675899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 11675899 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 123
Study 9135352 — intervention group
Group type: EXPERIMENTAL
Intervention: Light halothane anaesthesia (1% end-tidal concentration) with propofol (3 mg kg-1)
Number of subjects: 100
Study 9135352 — intervention group
Group type: COMPARATOR
Intervention: Deep halothane anaesthesia (2% end-tidal concentration)
Number of subjects: 100
Study 7957980 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 patch, 0.1 mg for 25 days each month (n = 7)
Number of subjects: 14
Study 7957980 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 with MPA, 10 mg from days 16 to 25 each month (n = 7)
Number of subjects: 14
Study 7957980 — intervention group
Group type: COMPARATOR
Intervention: Oral equine estrogens, 1.25 mg (n = 8)
Number of subjects: 14
Study 3621635 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (160-480 mg/day)
Number of subjects: 16
Study 3621635 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg/day) plus Hydralazine (50-200 mg/day)
Number of subjects: 16
Study 30121600 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBT)
Number of subjects: 88
Study 30121600 — intervention group
Group type: COMPARATOR
Intervention: Traditional balance training (control)
Number of subjects: 88
Study 26451695 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fat grafting
Number of subjects: 0
Study 26451695 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermis grafting
Number of subjects: 0
Study 25603750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation(®) (FM)
Number of subjects: 42
Study 25603750 — intervention group
Group type: COMPARATOR
Intervention: Low‐Level Laser Therapy (LLLT)
Number of subjects: 42
Study 23514286 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of patent foramen ovale
Number of subjects: 980
Study 23514286 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 980
Study 20978741 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI fruit intake
Number of subjects: 152
Study 20978741 — intervention group
Group type: COMPARATOR
Intervention: High fibre dietary advice
Number of subjects: 152
Study 18627642 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide/0.5% timolol fixed combination (DTFC)
Number of subjects: 232
Study 18627642 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 232
Study 16640481 — intervention group
Group type: EXPERIMENTAL
Intervention: VR distraction using Street Luge (5DT), presented via a head‐mounted display
Number of subjects: 20
Study 16640481 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (topical anesthetic) with no distraction
Number of subjects: 20
Study 16640481 — intervention group
Group type: EXPERIMENTAL
Intervention: VR distraction using Street Luge (5DT)
Number of subjects: 20
Study 12594778 — intervention group
Group type: EXPERIMENTAL
Intervention: High pesticide usage (1,3-dichloropropene, captafol, pentachloronitrobenzene, dieldrin)
Number of subjects: 102
Study 12594778 — intervention group
Group type: COMPARATOR
Intervention: Non-cancer deaths (control group)
Number of subjects: 102
Study 10642377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol after exercise (ExEt)
Number of subjects: 9
Study 10642377 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (Ex)
Number of subjects: 9
Study 10642377 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study 8797125 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent vertebral fractures (within the previous 4 years)
Number of subjects: 645
Study 8797125 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported disk problems
Number of subjects: 645
Study 8797125 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 645
Study 8797125 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of other painful joints
Number of subjects: 645